Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • lorendarith
    • Aug 2026

    #1

    Contaminants as a necessary evil?

    If you do any sort of adapter trimming (complete sequence, specific kmers, barcodes...) and completely make your data devoid of these sequences, wouldn't one also eliminate any actual biological sequence that bares resemblance to these contaminants?

    Wouldn't that cause a gap in the assemblies?

    Does any of this make sense? D:
  • mastal
    Senior Member
    • Mar 2009
    • 666

    #2
    Contaminants as a necessary evil?

    Yes, it makes sense.

    I guess when we do adapter trimming we are assuming that the adapters have been designed so that those sequences don't map anywhere in the genome.

    And there is obviously also a trade-off between removing all the contaminating adapter sequences and risking that in trimming too aggressively we will be removing some actual sequence that is not adapter.

    Comment

    • lorendarith

      #3
      Originally posted by mastal View Post
      I guess when we do adapter trimming we are assuming that the adapters have been designed so that those sequences don't map anywhere in the genome.
      Agreed, but I don't think there is a combination (of if there is prolly, not many possibilities?) of bases so the sequence doesn't turn up in one or the other genome.

      I tried blasting the first 25bp of the Illumina Truseq adapter against nt and you get quite some hits (genomes). Now, I don't know if the hits are actual biological sequences or leftover contaminants.

      One could test it against a Sanger sequenced genome...

      Comment

      • krobison
        Senior Member
        • Nov 2007
        • 734

        #4
        Most of the trimming you describe is applied only to the ends of reads, so the information will not be lost if it appears in the middle of reads.

        But, it is definitely true that you need to think carefully about what you are screening out entirely. You may lose something valuable!

        Comment

        • rskr
          Senior Member
          • Oct 2010
          • 249

          #5
          Yes and no. In theory you should be able to build a predictive model that accounts for a large percentage of your contaminants. IE if your adapter sequences matches at 18 bases and mismatches at three, then you could calculate the probability that it is an adapter vs. the alternative not an adapter, assuming an error rate of 95 percent in the sequencing.

          For many analysts analysis it doesn't matter, remapping for example, there is just a bunch of junk left over. Other times it only becomes a problem when it breaks things, for example when an assembly or mapping has millions of mappings in a single place and the algorithms developers didn't build the software to handle that situation. And the most interesting of course are when you get crazy small p-values in completely irrelevant genes.

          I think it is interesting to take common adapter sequences 454 for example and blast them against ncbi just to see what comes up.

          Comment

          Latest Articles

          Collapse

          • SEQadmin2
            Beyond CRISPR/Cas9: Understand, Choose, and Use the Right Genome Editing Tool
            by SEQadmin2



            CRISPR/Cas9 sparked the gene editing revolution for both research and therapeutics.1 But this system still showed severe issues that limited its applications. The most prominent were the heavy reliance on PAM sequences, delivery limitations, double-stranded breaks that prompt unintended edits and cell death, and editing inefficiency (both in targeting and in knock-in reliability).

            Despite this, “CRISPR helped turn genome editing from a specialized technique into
            ...
            07-31-2026, 11:01 AM
          • SEQadmin2
            Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
            by SEQadmin2


            Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

            The systematic characterization of the human proteome has
            ...
            07-20-2026, 11:48 AM

          ad_right_rmr

          Collapse

          News

          Collapse

          Topics Statistics Last Post
          Started by SEQadmin2, 08-06-2026, 07:41 AM
          0 responses
          14 views
          0 reactions
          Last Post SEQadmin2  
          Started by SEQadmin2, 08-03-2026, 10:13 AM
          0 responses
          31 views
          0 reactions
          Last Post SEQadmin2  
          Started by SEQadmin2, 07-31-2026, 02:55 AM
          0 responses
          40 views
          0 reactions
          Last Post SEQadmin2  
          Started by SEQadmin2, 07-24-2026, 12:17 PM
          0 responses
          26 views
          0 reactions
          Last Post SEQadmin2  
          Working...